BIO-11006 Inhalation Solution: Phase II started

BioMarck began the double-blind, placebo-controlled, U.S. Phase II BREATH-1 trial to evaluate 75, 150 or 250 mg of inhaled BIO-11006 given once daily for 3 weeks in 162 patients. ...